Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Cost of Revenue: 2021-2024

Historic Cost of Revenue for Zevra Therapeutics (ZVRA) over the last 4 years, with Dec 2024 value amounting to $7.4 million.

  • Zevra Therapeutics' Cost of Revenue fell 46.24% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year increase of 124.35%. This contributed to the annual value of $7.4 million for FY2024, which is 241.33% up from last year.
  • Per Zevra Therapeutics' latest filing, its Cost of Revenue stood at $7.4 million for FY2024, which was up 241.33% from $2.2 million recorded in FY2023.
  • Over the past 5 years, Zevra Therapeutics' Cost of Revenue peaked at $7.4 million during FY2024, and registered a low of $222,000 during FY2022.
  • For the 3-year period, Zevra Therapeutics' Cost of Revenue averaged around $3.3 million, with its median value being $2.2 million (2023).
  • In the last 5 years, Zevra Therapeutics' Cost of Revenue slumped by 89.22% in 2022 and then soared by 878.83% in 2023.
  • Zevra Therapeutics' Cost of Revenue (Yearly) stood at $2.1 million in 2021, then plummeted by 89.22% to $222,000 in 2022, then surged by 878.83% to $2.2 million in 2023, then soared by 241.33% to $7.4 million in 2024.